Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Pension (2023 - 2025)

Monte Rosa Therapeutics' Pension history spans 3 years, with the latest figure at $5.3 million for Q4 2025.

  • For Q4 2025, Pension rose 42.22% year-over-year to $5.3 million; the TTM value through Dec 2025 reached $5.3 million, up 42.22%, while the annual FY2025 figure was $5.3 million, 42.22% up from the prior year.
  • Pension reached $5.3 million in Q4 2025 per GLUE's latest filing, up from $4.7 million in the prior quarter.
  • In the past five years, Pension ranged from a high of $12.0 million in Q4 2023 to a low of $1.5 million in Q3 2023.
  • Average Pension over 3 years is $3.9 million, with a median of $3.3 million recorded in 2024.
  • The largest YoY upside for Pension was 94.29% in 2024 against a maximum downside of 69.22% in 2024.
  • A 3-year view of Pension shows it stood at $12.0 million in 2023, then plummeted by 69.22% to $3.7 million in 2024, then soared by 42.22% to $5.3 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Pension are $5.3 million (Q4 2025), $4.7 million (Q3 2025), and $4.6 million (Q2 2025).